Invasive Brain-Computer Interface Receives First Approval in China, Driving Attention to Healthcare Innovation ETF (516820)

As of March 16, 2026, 10:01, the constituent stocks of the CSI Pharmaceutical and Medical Device Innovation Index (931484) showed mixed gains and losses.Pien Tze HuangUp 2.39%,Sino CellsIncreased by 2.01%,Huitai MedicalIncrease by 1.38%;Intco MedicalLeading the decline. The latest quote for the Healthcare Innovation ETF (516820) is 0.36 yuan.

In terms of liquidity, the medical innovation ETF had a turnover rate of 0.38% during the trading day, with a transaction volume of 7.0469 million yuan. Looking at a longer time frame, as of March 13, the medical innovation ETF averaged a daily turnover of 51.3617 million yuan over the past year. In terms of scale, the latest size of the medical innovation ETF has reached 1.842 billion yuan. (Data source: Wind)

In terms of news, the first regulatory approval for invasive brain-computer interfaces has been granted. On March 13, Neuracle's implantable brain-computer interface system for hand motor function compensation received NMPA approval for marketing, entering clinical application as the world’s first invasive brain-computer interface medical device. The product employs epidural minimally invasive implantation and wireless power supply communication technology, designed for patients with quadriplegia caused by C2-C6 cervical spinal cord injuries. This milestone event marks that China's brain-computer interface industry has achieved a synchronized closed loop in top-level design and regulatory practice, transitioning from early conceptual R&D to later clinical applications.

Century Securities believes that brain-computer interface, as a multidisciplinary and future-oriented industry, has already gained a first-mover advantage in clinical progress in China. Approved devices will gradually enter hospitals to accumulate real-world data, and the underlying software and hardware platforms, which have verified safety, are expected to continuously iterate, optimize, and expand indications. It is recommended to pay attention to specialized medical service providers who control core neurosurgical clinical resources and data entry points, as well as companies with invasive brain-computer interface technology platforms.Innovative HealthcareInstrument Company.

The Medical Innovation ETF closely tracks the CSI Pharmaceutical and Medical Device Innovation Index. The CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed company securities with better profitability, certain growth potential, and R&D innovation capabilities from the pharmaceutical and healthcare industry, serving as index samples to reflect the overall performance of listed companies in the pharmaceuticals and medical devices sectors that combine profitability with growth.

Data shows that as of February 27, 2026, the top ten weighted stocks of the CSI Pharmaceutical and Medical Device Innovation Index (931484) are respectivelyWuXi AppTec、Mindray Medical、Hengrui Medicine、Aier Eye Hospital, Pien Tze Huang,Xinhé Chéng、Huadong Medicine、Pharmaron、Elis、Dong'e Ejiao, the top ten weighted stocks account for a combined 63.75%.

Risk Warning: Funds involve risks, and investments should be made with caution. The fund manager commits to managing and utilizing the fund assets in accordance with the principles of honesty, credibility, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit or achieve the minimum return. The fund manager reminds investors of the principle of "buyer beware" in fund investment. After making an investment decision, the investment risks arising from changes in the fund's operational status and net asset value are borne by the investors themselves. The past performance and net asset value fluctuations of the fund do not predict its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee of this fund’s performance. Investors purchasing funds may share in the returns generated by the fund investment according to their holding shares, but they may also bear the losses brought about by the fund investment. Investors should carefully read legal documents such as the 'Fund Contract' and 'Prospectus' to fully understand the risk-return characteristics and product features of this fund. They should assess whether the fund aligns with their own risk tolerance based on their investment objectives, investment horizon, investment experience, and asset conditions, rationally judge the market, and prudently make investment decisions. Relevant information in this material is sourced from publicly available data considered reliable by the fund manager. Related views, assessments, and forecasts reflect current judgments only and are subject to change subsequently. Any market views contained in this material are based on corresponding assumptions, and any such assumptions may change at any time. The fund manager does not promise or guarantee that any predictive market views will necessarily be realized. Individual stocks mentioned in the material do not constitute investment recommendations or advice. The secondary market price fluctuations of ETF funds do not represent actual fund returns; investors should be aware of the risks associated with intraday price volatility.